undamentalytics Newsletter
Sign in

Retractable Technologies Inc (RVP) stock

Add to watchlist

Add holding +

NYSE: RVP NYSE Health Care Equipment

D Fundamentals grade

Retractable Technologies Inc is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$0.0

Revenue-to-maturity cash-flow model

Base case. Range ~$0.0–$0.2 across our lower- and higher-growth cases (0%–5% a year).

Price vs value

No Buy/Hold/Sell rating is issued: only 2 valuation models apply; a rating needs 3.

Retractable Technologies Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling3 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds10 adding, 6 cuttingOf 2 active managers that changed their stake, 2 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Retractable Technologies files

Where Retractable Technologies stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $34m, down 11.2% on a year earlier, against growth of 10.1% a quarter earlier. That puts it 93 of 103 for growth among the health care equipment companies we cover. Free-cash-flow margin fell to -37.7% from -35.5% a year earlier. Operating margin narrowed to -66.9% from -58.1%. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 3 financial-health checks. Our revenue-to-maturity cash-flow model value is $0.05 a share.

Source: 10-Q filed August 14, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Retractable Technologies Inc's trailing-twelve-month revenue fell 11.2% year on year, with a free-cash-flow margin of -37.7%. Where it stands out: long-term debt as % of assets of 0.6% ranks 11 of 87 health care equipment companies we cover. Where it lags: gross margin of -1.4% ranks 121 of 123 health care equipment companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 5.8% while net income grew 61.4%: a 56pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Retractable Technologies Inc's latest figures clears our strength thresholds.

Things to watch

  • Revenue shrinking. Revenue fell 11.2% over the last 12 months.
  • Growth slowing. The growth rate is 21.2 points lower than a quarter earlier.
  • Loss-making. Operating margin is -66.9%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 8.8 points on a year ago.
  • Burning cash. Free cash flow was -37.7% of revenue over the last 12 months.
  • Below peers: gross margin. Gross margin of -1.4% ranks 121 of 123 health care equipment companies we cover (median 61.9%).

Latest results: FY2026 Q2

Filed August 14, 2026
Earnings per share
-$0.04 against an average estimate of $0.01: missed by 366.7%
Revenue
$7m, down 31.1% on a year earlier

Retractable Technologies' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.9%
  • 1 week-4.2%
  • 1 month-19.3%
  • This year-26.0%
  • 1 year-35.8%
  • 5 years-94.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$33.9M
Operating margin
-66.9%
Net margin
-9.9%
EPS (TTM, diluted)
$-0.11

Growth

Revenue growth
−11.2%
Change in growth rate
−21.2 pts
Share count change
+0.0%

Cash

Free cash flow (TTM)
-$12.8M
FCF margin
-37.7%

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Retractable Technologies Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 2 valuation models apply; a rating needs 3.

Valuation models

We value Retractable Technologies Inc as an operating company, with every model that fits that kind of business. Cost of equity 8.5%: the 10-year Treasury yield (4.9%) plus a beta of 0.8 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$0.0 ~$0.0–$0.2 Left out: out of range vs price (0.05x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$0.4 ~$0.2–$0.7 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$1.1 ~$1.3–$5.6 Included, half weight
Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$0.6 ~$0.4–$1.1 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Retractable Technologies Inc with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$3.10$0.93$0.68$0.60$1.50$10.74$6.93$1.64$1.11$0.69$0.77$0.57
Market value$91m$27m$22m$20m$49m$358m$237m$54m$33m$21m$23m$17m
+ Net debt (− = net cash)−$14m−$12m−$11m−$7m−$3m−$14m−$27m−$18m−$11m−$3m−$2m−$2m
Enterprise value$77m$15m$10m$13m$46m$344m$210m$36m$22m$18m$21m$15m
Multiples
Price / sales 3.1x0.9x0.6x0.6x1.2x4.4x1.3x0.6x0.8x0.6x0.6x0.5x
Price / earnings 21.2x———15.6x14.8x4.2x10.6x————
Price / free cash flow ————31.4x———17.4x———
EV / EBITDA ————12.0x13.8x2.8x9.6x————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

30 /100

Weak moat

How hard Retractable Technologies's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -6.6% of total assets over 10 years.

  • Pricing power 3 / 20

    Gross margin has been a median 29.8%, moving by 17.2 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -10.7%; its worst year was -66.9%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 2 of 10 years, at a median -8.9% of revenue.

  • Discipline 15 / 20

    The diluted share count fell 12.1% over five years; stock-based pay has been a median 6.3% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Retractable Technologies Inc: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Dec 2010 $0.01 −$0.04 −366.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest
0.2%
of tradable shares
Days to cover
0.76
at average volume
Short interest, 1 month
−56%
to October 15, 2026
Held by institutions
9%
of shares
Held by insiders
59.2%
of shares
Employees
195
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −35.2%

$0.88 on October 31, 2025 to $0.57

ThenNowEffect
Revenue (last 12 months) $38m $34m −11.2%
P/S multiple 0.7x 0.5x −27.1%
Share count 30m 30m 0.0%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −48.6%

$1.11 on November 3, 2023 to $0.57

ThenNowEffect
Revenue (last 12 months) $55m $34m −38.0%
P/S multiple 0.6x 0.5x −20.7%
Share count 31m 30m +4.5%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
RVP−36%−76%−32%−38%+12%−26%
Industry peers (median)−7%−37%−8%−19%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
RVP33%33%50%42%42%27%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
RVP−69%−77%−52%−58%−27%−27%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 97% from February 1, 2021 to November 18, 2024. Getting back needed a 3672% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.57 – $0.88
From 52-week high
−35.2%
vs 50-day average
−14.2%
vs 200-day average
−16.3%
Volatility (1 year)
40%
Beta vs S&P 500
0.21

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Retractable Technologies Inc in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Retractable Technologies Inc
$30M $35M $40M $45M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $42M Revenue (TTM), FY23 Q4: $43.6M Revenue (TTM), FY24 Q1: $40.2M Revenue (TTM), FY24 Q2: $38.3M Revenue (TTM), FY24 Q3: $38.3M Revenue (TTM), FY24 Q4: $33M Revenue (TTM), FY25 Q1: $33.7M Revenue (TTM), FY25 Q2: $38.2M Revenue (TTM), FY25 Q3: $37.9M Revenue (TTM), FY25 Q4: $38.3M Revenue (TTM), FY26 Q1: $37.1M Revenue (TTM), FY26 Q2: $33.9M $33.9M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $42M
FY23 Q4 $43.6M
FY24 Q1 $40.2M
FY24 Q2 $38.3M
FY24 Q3 $38.3M
FY24 Q4 $33M
FY25 Q1 $33.7M
FY25 Q2 $38.2M
FY25 Q3 $37.9M
FY25 Q4 $38.3M
FY26 Q1 $37.1M
FY26 Q2 $33.9M
Revenue growth, TTM YoY Retractable Technologies Inc
-100% -50% 0% 50% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -70.3% Revenue growth, TTM YoY, FY23 Q4: -54.0% Revenue growth, TTM YoY, FY24 Q1: -34.2% Revenue growth, TTM YoY, FY24 Q2: -30.1% Revenue growth, TTM YoY, FY24 Q3: -8.9% Revenue growth, TTM YoY, FY24 Q4: -24.2% Revenue growth, TTM YoY, FY25 Q1: -16.0% Revenue growth, TTM YoY, FY25 Q2: -0.2% Revenue growth, TTM YoY, FY25 Q3: -1.0% Revenue growth, TTM YoY, FY25 Q4: 15.8% Revenue growth, TTM YoY, FY26 Q1: 10.1% Revenue growth, TTM YoY, FY26 Q2: -11.2% -11.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -70.3%
FY23 Q4 -54.0%
FY24 Q1 -34.2%
FY24 Q2 -30.1%
FY24 Q3 -8.9%
FY24 Q4 -24.2%
FY25 Q1 -16.0%
FY25 Q2 -0.2%
FY25 Q3 -1.0%
FY25 Q4 15.8%
FY26 Q1 10.1%
FY26 Q2 -11.2%
Operating margin (TTM) Retractable Technologies Inc
-80% -60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -39.4% Operating margin (TTM), FY23 Q4: -26.4% Operating margin (TTM), FY24 Q1: -29.2% Operating margin (TTM), FY24 Q2: -32.6% Operating margin (TTM), FY24 Q3: -43.5% Operating margin (TTM), FY24 Q4: -63.9% Operating margin (TTM), FY25 Q1: -67.6% Operating margin (TTM), FY25 Q2: -58.1% Operating margin (TTM), FY25 Q3: -54.6% Operating margin (TTM), FY25 Q4: -55.3% Operating margin (TTM), FY26 Q1: -61.0% Operating margin (TTM), FY26 Q2: -66.9% -66.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -39.4%
FY23 Q4 -26.4%
FY24 Q1 -29.2%
FY24 Q2 -32.6%
FY24 Q3 -43.5%
FY24 Q4 -63.9%
FY25 Q1 -67.6%
FY25 Q2 -58.1%
FY25 Q3 -54.6%
FY25 Q4 -55.3%
FY26 Q1 -61.0%
FY26 Q2 -66.9%
FCF margin (TTM) Retractable Technologies Inc
-40% -20% 0% 20% 40% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 22.3% FCF margin (TTM), FY23 Q4: 4.4% FCF margin (TTM), FY24 Q1: 9.5% FCF margin (TTM), FY24 Q2: 11.3% FCF margin (TTM), FY24 Q3: -25.8% FCF margin (TTM), FY24 Q4: -39.3% FCF margin (TTM), FY25 Q1: -36.5% FCF margin (TTM), FY25 Q2: -35.5% FCF margin (TTM), FY25 Q3: -22.1% FCF margin (TTM), FY25 Q4: -38.8% FCF margin (TTM), FY26 Q1: -39.7% FCF margin (TTM), FY26 Q2: -37.7% -37.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 22.3%
FY23 Q4 4.4%
FY24 Q1 9.5%
FY24 Q2 11.3%
FY24 Q3 -25.8%
FY24 Q4 -39.3%
FY25 Q1 -36.5%
FY25 Q2 -35.5%
FY25 Q3 -22.1%
FY25 Q4 -38.8%
FY26 Q1 -39.7%
FY26 Q2 -37.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 39 36 32 34 31 35 30 30 34 33 42 82 188 95 44 33 38 34
Gross profit 14 13 11 11 10 12 11 10 10 10 14 37 95 28 9 −1 0 −0
EBITDA −12 −5 −3 −3 −5 −1 −2 −3 −3 −0 4 25 74 4 −4 −14 −13 −15
Operating income −13 −7 −4 −4 −6 −2 −3 −4 −4 −1 3 24 73 −1 −11 −21 −21 −23
Net income −9 2 1 −4 −6 −2 4 −4 −4 −1 3 24 56 5 −7 −12 −13 −3
Diluted EPS −$0.45 $0.04 $0.02 −$0.19 −$0.26 −$0.12 $0.20 −$0.15 −$0.14 −$0.06 $0.07 $0.80 $1.63 $0.15 −$0.24 −$0.40 −$0.43 −$0.11
Growth (year on year)
Revenue — −7.1% −11.4% +4.8% −8.5% +12.1% −14.4% +0.9% +15.6% −3.5% +25.6% +95.9% +130.1% −49.7% −54.0% −24.2% +15.8% −11.2%
EBITDA — — — — — — — — — — — +551.2% +196.6% −94.9% −205.6% — — —
Operating income — — — — — — — — — — — +710.0% +201.6% −101.2% — — — —
Net income — — −40.9% −391.4% — — — −185.6% — — — +669.4% +131.5% −90.9% −238.1% — — —
Diluted EPS — — −50.0% <−999% — — — −175.0% — — — +>999% +103.8% −90.8% −260.0% — — —
Margins
Gross margin 34.7% 34.6% 34.0% 33.2% 33.5% 34.8% 35.8% 34.7% 28.9% 30.7% 33.8% 45.2% 50.6% 29.8% 20.9% −3.1% 0.1% −1.4%
EBITDA margin −30.5% −14.2% −8.7% −7.7% −15.1% −3.1% −8.0% −8.8% −8.5% −1.3% 9.1% 30.4% 39.2% 4.0% −9.1% −41.0% −35.0% −43.9%
Operating margin −34.1% −18.4% −12.7% −11.7% −19.3% −6.3% −10.9% −11.8% −11.0% −4.0% 7.1% 29.4% 38.5% −0.9% −26.4% −63.9% −55.3% −66.9%
Net margin −24.2% 6.6% 4.4% −12.3% −20.2% −6.8% 14.6% −12.4% −10.8% −4.0% 7.5% 29.6% 29.8% 5.4% −16.1% −36.0% −32.8% −9.9%
Free-cash-flow margin −37.7% 23.6% 14.6% −1.0% 8.6% −14.1% −16.0% −9.2% −8.7% −4.7% 3.7% −2.5% −13.6% −0.1% 4.4% −39.3% −18.5% −14.6%
Cash flow
Cash from operations −12 9 6 0 3 −4 −3 −1 −3 −1 2 19 33 17 3 −12 −7 −5
Capital spending 2 0 1 1 0 1 1 2 0 0 1 21 58 17 1 1 0 0
Free cash flow −15 9 5 −0 3 −5 −5 −3 −3 −2 2 −2 −26 −0 2 −13 −7 −5
Stock-based pay 2 1 0 0 0 0 0 0 1 0 0 0 4 10 0 0 — —
Free cash flow after stock pay −17 7 5 −0 3 −5 −5 −3 −4 −2 2 −2 −29 −10 2 −13 — —
Balance sheet
Cash 18 23 26 26 22 18 18 16 15 10 6 18 29 20 13 4 3 3
Total debt 0 5 5 4 4 4 4 4 3 3 3 4 2 2 2 1 1 1
Net debt (negative = net cash) −18 −18 −21 −22 −18 −14 −14 −12 −11 −7 −3 −14 −27 −18 −11 −3 −2 −2
Diluted shares 24m 26m 26m 26m 27m 27m 29m 29m 32m 33m 33m 33m 34m 33m 30m 30m 30m 30m
Returned to shareholders
Buybacks — — — 0 1 — — — — — — — 5 8 — — — —
Total returned — — — 0 1 — — — — — — — 5 8 — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · June 30, 2026
What it owns · $142m
Short-term assets $66mLonger-term assets $76m
What it owes, and who funded it · $142m
Short-term liabilities $13mLonger-term liabilities $55mShareholders' equity $73m
  • Short-term assets cover short-term liabilities $66m of assets due within a year against $13m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $66m short-term assets against $55m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$23m against $81,340 of interest.

From Retractable Technologies Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+0.0%
year over year
R&D spending
2.0%
of revenue
Days sales outstanding
97 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated RVP OBIO UTMD POCI ECOR CTSO Median
Revenue, last 12 months $34m $32m $36m $32m $37m $37m $99m
Revenue growth, last 12 months −11.2% 986.1% −7.0% 65.2% 33.5% 3.1% 9.2%
Revenue growth, 3-year average −14.7% 94.5% −11.4% 14.4% 50.4% 0.8% 13.5%
Revenue growth, latest quarter −31.1% −89.5% −14.3% 42.0% 28.0% 0.2% 10.2%
Gross margin −1.4% 99.5% 57.9% 17.2% 87.1% 71.6% 61.2%
Operating margin −66.9% −181.4% 28.4% −11.1% −37.6% −34.7% −8.5%
Operating margin, 3-year average −52.5% <−999% 31.2% −18.2% −51.0% −49.7% −17.9%
Net margin −9.9% −184.6% 29.0% −11.5% −40.0% −48.9% −12.0%
Cash from operations / revenue −14.6% −182.4% 32.8% −4.9% −26.3% −24.6% −1.9%
Free-cash-flow margin −37.7% −184.8% 31.7% −5.8% −26.4% −25.0% −3.9%
Free-cash-flow margin, 3-year average −20.6% <−999% 35.4% −13.4% <−999% −37.9% −7.0%
Stock pay / revenue 10.7% 34.8% 1.1% 3.5% 7.2% 6.1% 6.1%
Change in share count 0.0% 58.1% −4.8% 25.6% 8.5% 4.1% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth -11.2% 9.1% 113 of 129
Change in growth rate Growth -21.2pp -0.6pp 119 of 129
Gross margin Profitability -1.4% 61.9% 121 of 123
Operating margin Profitability -66.9% -8.3% 92 of 132
Net margin Profitability -9.9% -12.0% 60 of 133
Free-cash-flow margin Cash generation -37.7% -3.4% 90 of 128
Long-term debt as % of assets Balance sheet 0.6% 24.2% 11 of 87
Change in share count Balance sheet 0.0% 3.3% 33 of 115
Days sales outstanding Balance sheet 97 days 57 days 107 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Syringes $24.9M 65.1% ▲ 10.1%
Easy Point Needles $11.9M 31.2% ▲ 33.5%
Blood Collection Products $1.4M 3.6% ▼ 3.9%
Other Products $43,627 0.1% ▼ 4.9%

From Retractable Technologies Inc's 10-K filed March 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$1.9M
Institutions reporting
32
Shares held vs prior quarter
▲ 5.9%
Positions opened / closed
5 / 2

Top buyers and sellers, Q2 2026: 10 institutions bought and 6 sold ; the biggest buyer was Citadel Advisors LLC (+87K shares) and the biggest seller Geode Capital Management, LLC (−28K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Vanguard Capital Management LLC $418,850 582K 22.1% 0.0%
Eversept Partners, LP $418,262 581K 22.0% 0.0%
Renaissance Technologies LLC $317,813 441K 16.7% ▲ 9.3%
Blackrock, Inc. $173,607 241K 9.1% 0.0%
Geode Capital Management, LLC $87,141 121K 4.6% ▼ 19.0%
Bridgeway Capital Management, LLC $63,751 89K 3.4% 0.0%
Citadel Advisors LLC $62,880 87K 3.3% New
Vanguard Fiduciary Trust Co $61,387 85K 3.2% 0.0%
Susquehanna International Group, LLP $56,777 79K 3.0% ▲ 140.0%
State Street Corp $43,053 60K 2.3% 0.0%
Wealthtrust Axiom LLC $36,959 51K 1.9% ▼ 2.8%
LPL Financial LLC $34,248 48K 1.8% ▼ 5.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Retractable Technologies Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $10,719 3 trades by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $10,719 net buying
Insider Date Trade Shares Price Value
Shaw Thomas J PRESIDENT AND CEO November 14, 2025 Buy pre-set plan 5,731 $0.77 $4,413
Shaw Thomas J PRESIDENT AND CEO November 11, 2025 Buy pre-set plan 100 $0.81 $81
Shaw Thomas J PRESIDENT AND CEO November 5, 2025 Buy pre-set plan 7,500 $0.83 $6,225

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Retractable Technologies Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Retractable Technologies Inc in brief

What does Retractable Technologies Inc do?
Retractable Technologies Inc is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Retractable Technologies Inc's stock ticker?
Retractable Technologies Inc trades under the ticker RVP on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Retractable Technologies Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Retractable Technologies Inc reported revenue of $33.9M, 11.2% lower than a year earlier, according to its SEC filings.
What is Retractable Technologies Inc's free cash flow?
Retractable Technologies Inc's free-cash-flow margin is -37.7% of revenue over the trailing twelve months, ranking 90 of the 128 health care equipment companies we cover.
Who are Retractable Technologies Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Vanguard Capital Management LLC, Eversept Partners, LP and Renaissance Technologies LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Retractable Technologies Inc's market cap?
On November 2, 2026, Retractable Technologies Inc's market capitalisation was about $17.1M and net debt of -$1.7M. Market figures come from third-party market data and may be delayed.
Who are Retractable Technologies Inc's competitors?
In our Health Care Equipment peer group, the companies closest to Retractable Technologies Inc are Orchestra Biomed Holdings, Inc., Utah Medical Products Inc, Precision Optics Corporation, Inc., Electrocore, Inc. and Cytosorbents Corp. The side-by-side comparison below sets their revenue, margins and growth against Retractable Technologies Inc's.
Are insiders buying or selling Retractable Technologies Inc stock?
Over the last 12 months, Retractable Technologies Inc's directors and officers reported 3 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.